Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cipla
Accenture
Queensland Health
Boehringer Ingelheim
Cerilliant
US Army
Mallinckrodt
Express Scripts

Generated: June 23, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,285,668

« Back to Dashboard

Summary for Patent: 7,285,668
Title:Process for the crystallization of (R)- or (S)-lansoprazole
Abstract:The present invention relates to a production method of a crystal of (R)-lansoprazole or (S)-lansoprazole, which includes crystallization at a temperature of about 0.degree. C. to about 35.degree. C. from a C.sub.1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole at a concentration of about 0.1 g/mL to about 0.5 g/mL and the like. According to the production method of the present invention, a crystal of (R)-lansoprazole or (S)-lansoprazole superior in preservation stability can be produced efficiently on an industrial large scale.
Inventor(s): Hashimoto; Hideo (Kobe, JP), Urai; Tadashi (Kawanishi, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:10/432,798
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,285,668
Patent Claims: 1. A method for producing a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole or (S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole, which comprises crystallizing at a temperature of about 0.degree. C. to about 35.degree. C. from a C.sub.1-4 alkyl acetate solution containing (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole or (S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole at a concentration of about 0.1 g/mL to about 0.5 g/mL.

2. A method for producing a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole or (S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole, which comprises crystallizing at a temperature of about 0.degree. C. to about 35.degree. C. from a C.sub.1-4 alkyl acetate solution containing (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole or (S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole at a concentration of about 0.1 g/mL to about 0.5 g/mL, and adding dropwise to the C.sub.1-4 alkyl acetate solution, at the same temperature, C.sub.5-8 hydrocarbon in an amount of not more than 7 times the amount of the C.sub.1-4 alkyl acetate solution.

3. The method of claim 1, wherein the crystallization temperature is about 20.degree. C. to about 30.degree. C.

4. The method of claim 1, wherein the crystallization is conducted for about 30 minutes to about 4 hours.

5. The method of claim 1, wherein the C.sub.1-4 alkyl acetate is ethyl acetate or propyl acetate.

6. The method of claim 2, wherein the C.sub.5-8 hydrocarbon is added in an amount of not more than 5 times the amount of the C.sub.1-4 alkyl acetate solution.

7. The method of claim 2, wherein the C.sub.5-8 hydrocarbon is heptane or hexane.

8. The method of claim 2, wherein the C.sub.5-8 hydrocarbon is added dropwise over about 15 minutes to about 4 hours.

9. A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole or (S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole having a melting start temperature of not lower than about 131.degree. C.

10. The crystal of claim 9, wherein the melting start temperature is about 135.degree. C.

11. The method of claim 2, wherein the crystallization temperature is about 20.degree. C. to about 30.degree. C.

12. The method of claim 2, wherein the crystallization is conducted for about 30 minutes to about 4 hours.

13. The method of claim 2, wherein the C.sub.1-4 alkyl acetate is ethyl acetate or acetate.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Cipla
Fuji
UBS
Farmers Insurance
Healthtrust
Harvard Business School
US Department of Justice
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.